Q1 financial 2025
Category: dates
Transgene Provides Business and Financial Update for Q1 2025
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025
AG 2025
Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025
ASCO 2025 curtain
Availability of Transgene’s 2024 Universal Registration Document (URD)
URD 2024
Van Lanschot Kempen Life Sciences Conference (Amsterdam, Netherlands)- April 2, 2025
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations
CTO Appointment
Investor Access Event (Paris) – April 1, 2025
2024 Full-year results and 2025 outlook
link to webcast
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine – Strong Outlook for 2025
2024 Annual Results